Dateline City:
KENILWORTH, N.J.
Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from the initial phase (Part
A) of the companys C-CREST 1 and 2 Phase 2
clinical development program evaluating two investigational all-oral,
triple-combination treatment regimens a regimen of grazoprevir1,
MK-36822 and elbasvir3; and a regimen
of grazoprevir, MK-3682 and MK-84084 in treatment-nave
patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3
infection.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more